Oncternal Therapeutics, Inc.
ONCT · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $31,517 | $52,594 | $731,548 | $2,426,676 |
| - Cash | $6,697 | $37,142 | $90,765 | $116,737 |
| + Debt | $318 | $87 | $75 | $40 |
| Enterprise Value | $25,138 | $15,539 | $640,858 | $2,309,979 |
| Revenue | $785 | $1,490 | $4,315 | $3,375 |
| % Growth | -47.3% | -65.5% | 27.9% | – |
| Gross Profit | -$28,968 | $1,311 | $4,146 | -$8,625 |
| % Margin | -3,690.2% | 88% | 96.1% | -255.6% |
| EBITDA | $2,235 | -$44,947 | -$31,164 | -$17,392 |
| % Margin | 284.7% | -3,016.6% | -722.2% | -515.3% |
| Net Income | -$39,479 | -$43,393 | -$31,300 | -$17,209 |
| % Margin | -5,029.2% | -2,912.3% | -725.4% | -509.9% |
| EPS Diluted | -13.43 | -16.5 | -1.94 | -0.69 |
| % Growth | 18.6% | -750.5% | -181.2% | – |
| Operating Cash Flow | -$32,164 | -$36,704 | -$26,589 | -$17,495 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$32,164 | -$36,704 | -$26,589 | -$17,495 |